Bex M - Search Results

1

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.

Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G. Verhelst JA, et al. Among authors: bex m. Eur J Endocrinol. 2000 Nov;143(5):577-84. doi: 10.1530/eje.0.1430577. Eur J Endocrinol. 2000. PMID: 11078980 Clinical Trial.

2

The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.

Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. Bex M, et al. J Bone Miner Res. 2002 Jun;17(6):1081-94. doi: 10.1359/jbmr.2002.17.6.1081. J Bone Miner Res. 2002. PMID: 12054164 Free article. Clinical Trial.

3

Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.

Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A, Ilondo MM, Zdravkovic M, Bengtsson BA, Korbonits M; NN703 Clinical Research Group. Svensson J, et al. Among authors: bex m. Clin Endocrinol (Oxf). 2003 May;58(5):572-80. doi: 10.1046/j.1365-2265.2003.01754.x. Clin Endocrinol (Oxf). 2003. PMID: 12699438 Clinical Trial.

4

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.

Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ; Group for Lanreotide Autogel Long-Term Study on Acromegaly. Caron P, et al. Among authors: bex m. Clin Endocrinol (Oxf). 2004 Jun;60(6):734-40. doi: 10.1111/j.1365-2265.2004.02045.x. Clin Endocrinol (Oxf). 2004. PMID: 15163338

5

AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D. Bex M, et al. Eur J Endocrinol. 2007 Oct;157(4):399-409. doi: 10.1530/EJE-07-0358. Eur J Endocrinol. 2007. PMID: 17893253

6

T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R. T'Sjoen G, et al. Among authors: bex m. Eur J Endocrinol. 2007 Oct;157(4):411-7. doi: 10.1530/EJE-07-0356. Eur J Endocrinol. 2007. PMID: 17893254

7

Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly.

Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Alexopoulou O, et al. Among authors: bex m. J Clin Endocrinol Metab. 2008 Apr;93(4):1324-30. doi: 10.1210/jc.2007-2104. Epub 2008 Jan 29. J Clin Endocrinol Metab. 2008. PMID: 18230660

8

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.

Verhelst J, Velkeniers B, Maiter D, Haentjens P, T'Sjoen G, Rietzschel E, Corvilain B, Abrams P, Nobels F, Abs R, Bex M. Verhelst J, et al. Among authors: bex m. Eur J Endocrinol. 2013 Jan 17;168(2):177-84. doi: 10.1530/EJE-12-0753. Print 2013 Feb. Eur J Endocrinol. 2013. PMID: 23132698

9

Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Alexopoulou O, et al. Among authors: bex m. Pituitary. 2014 Feb;17(1):81-9. doi: 10.1007/s11102-013-0471-7. Pituitary. 2014. PMID: 23446424

10

Giant prolactinomas in women.

Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D. Delgrange E, et al. Among authors: bex m. Eur J Endocrinol. 2013 Nov 22;170(1):31-8. doi: 10.1530/EJE-13-0503. Print 2014 Jan. Eur J Endocrinol. 2013. PMID: 24088550 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters